2023-03-07 07:03:53 ET
- Alaunos Therapeutics press release ( NASDAQ: TCRT ): Q4 GAAP EPS of -$0.04 beats by $0.03 .
- As of December 31, 2022, Alaunos had approximately $53.0 million in cash balances, which includes restricted cash of approximately $13.9 million.
- Based on current operating plans, the Company expects its operating outflows, excluding debt service costs, for 2023 to be between approximately $35 million and $40 million. The Company expects to have sufficient cash resources to fund research and development programs and operations into the fourth quarter of 2023.
For further details see:
Alaunos Therapeutics GAAP EPS of -$0.04 beats by $0.03